Polar Asset Management Partners’s SAB Biotherapeutics Warrant SABSW Stock Holding History

Polar Asset Management Partners’s Portfolio SABSW Stock Details SABSW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-175,100	Closed	-$161K	–	1483
2021 Q3	$161K	Hold	175,100	–	–	﹤0.01%	1029
2021 Q2	$161K	Sell	175,100 -74,900	-30%	-$54.4K	﹤0.01%	963
2021 Q1	$150K	Buy	+250,000	New	+$260K	﹤0.01%	818

Other funds holding SABSW

SCM

Shaolin Capital Management Miami, Florida $2.71B AUM 64.57% 1-Year Est. Return

RCM

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

YCM

Yakira Capital Management Westport, Connecticut $342M AUM 26.95% 1-Year Est. Return

LMR Partners London, United Kingdom $45.4B AUM 60.47% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

ICMH

Integrity Capital Management (HK) Central, Hong Kong $64K AUM

Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return

RCM

Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return

EPM

Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

Polar Asset Management Partners's SABSW Position: Q4 2021 in Review

Polar Asset Management Partners sold out of SAB Biotherapeutics Warrant (SABSW) in Q4 2021, closing a stake of 175,100 shares — an estimated $161K sold.

Polar Asset Management Partners first reported a position in SABSW in Q1 2021 and held it in 3 quarters. The position peaked at $161K in Q3 2021. 21 funds tracked by Wall St. Rank hold SABSW as of Q4 2021.

Polar Asset Management Partners reported no remaining SAB Biotherapeutics Warrant position as of Q4 2021 after selling out during the quarter.
Polar Asset Management Partners sold 175,100 SAB Biotherapeutics Warrant shares in Q4 2021, an estimated $161K.
Polar Asset Management Partners first reported a position in SAB Biotherapeutics Warrant in Q1 2021 and held it in 3 quarters.
Polar Asset Management Partners's SAB Biotherapeutics Warrant position peaked at $161K in Q3 2021.
21 funds tracked by Wall St. Rank held SAB Biotherapeutics Warrant as of Q4 2021.

Based on Polar Asset Management Partners's 13F filing for Q4 2021, filed 14 Feb 2022.